433 related articles for article (PubMed ID: 29530767)
1. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation.
Liu L; Zhang X; Feng S
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1341-1349. PubMed ID: 29530767
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
[TBL] [Abstract][Full Text] [Related]
3. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
Solano C; Mateo EM; Pérez A; Talaya A; Terol MJ; Albert E; Giménez E; Vinuesa V; Piñana JL; Boluda JCH; Navarro D
J Clin Virol; 2017 Dec; 97():26-32. PubMed ID: 29096390
[TBL] [Abstract][Full Text] [Related]
5. Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello A; Piñana JL; Bataller L; Montoro J; Romero S; Navarro I; Lorenzo I; Andreu R; Guerreiro M; Aguilar C; Gorriz D; Dominguez L; de la Puerta R; Gómez I; Solves P; Jarque I; Sanz MÁ; Sanz G; Sanz J
Transplant Cell Ther; 2021 Mar; 27(3):261.e1-261.e7. PubMed ID: 33781531
[TBL] [Abstract][Full Text] [Related]
6. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
7. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
Ru Y; Chen J; Wu D
Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
[TBL] [Abstract][Full Text] [Related]
11. Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.
Pegoraro F; Favre C
Ann Hematol; 2021 Apr; 100(4):865-878. PubMed ID: 33547921
[TBL] [Abstract][Full Text] [Related]
12. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
van Esser JW; Niesters HG; van der Holt B; Meijer E; Osterhaus AD; Gratama JW; Verdonck LF; Löwenberg B; Cornelissen JJ
Blood; 2002 Jun; 99(12):4364-9. PubMed ID: 12036863
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
Kinch A; Hallböök H; Arvidson J; Sällström K; Bondeson K; Pauksens K
Leuk Lymphoma; 2018 May; 59(5):1172-1179. PubMed ID: 28831836
[TBL] [Abstract][Full Text] [Related]
15. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
16. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
[TBL] [Abstract][Full Text] [Related]
18. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.
Styczynski J; van der Velden W; Fox CP; Engelhard D; de la Camara R; Cordonnier C; Ljungman P;
Haematologica; 2016 Jul; 101(7):803-11. PubMed ID: 27365460
[TBL] [Abstract][Full Text] [Related]
19. Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation.
Liu L; Liu Q; Feng S
Ther Adv Hematol; 2020; 11():2040620720910964. PubMed ID: 32523657
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.
Takamatsu H; Araki R; Nishimura R; Yachie A; Espinoza JL; Okumura H; Yoshida T; Kuzushima K; Nakao S
J Clin Virol; 2016 Jul; 80():82-6. PubMed ID: 27218416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]